Series Editor:
Clive Page, King's College London, U.K.
Edited by
M. Davies, Strangeways Research Laboratories, Cambridge, U.K.
John Dingle, Strangeways Research Laboratories, Cambridge, U.K.
Description
The consequences for diseases involving the immune system such as AIDS, and chronic inflammatory diseases such as bronchial asthma, rheumatoid
athritis, and atherosclerosis, now account for a considerable economic burden to governments worldwide. In response there has been an
enormous research effort investigating the basic mechanisms underlying such diseases, and a tremendous drive to identify novel therapeutic
applications for their preventions and treatment. Though a plethora of immunological studies have been published in recent years, little
has been written about the implications of such research for drug development. As a consequence, this area has not gained the prominence
of other new fields such as molecular pharmacology or neuropharmacology, and a focal information source for many pharmacologists interested
in diseases of the immune system remains unpublished.
The Handbook of Immunopharmacology series provides such a source
through the commissioning of a comprehensive collection of volumes on all aspects immunopharmacology. Editors have been sought after
for each volume who are not only active in their respective areas of expertise, but who also have distinctly pharmacological bias to
their research. The series follows three main themes, each represented by volumes on individual component topics. The first covers each
of the major cell types and classes of inflammatory responses that can affect them ("Systems"). The third covers different classes of
diseases as well as those under development ("Drugs").
Included in series
Handbook of Immunopharmacology
